Intraneural Facilitation as a Treatment for Carpal Tunnel Syndrome

Sponsor
Loma Linda University (Other)
Overall Status
Completed
CT.gov ID
NCT03205683
Collaborator
(none)
10
1
2
12.8
0.8

Study Details

Study Description

Brief Summary

We hypothesize that a standard course of INF can result in significant improvement in CTS as measured by clinical, electrodiagnostic, or ultrasound measures.

Condition or Disease Intervention/Treatment Phase
  • Other: Intraneural facilitation (INF)
  • Other: Sham INF
N/A

Detailed Description

INF is a novel non-invasive therapy based on the principle of restoring vascular function at the capillary level in peripheral nerve. his therapy has been shown to improve clinical function in patients with diabetic-associated polyneuropathy, a model for various forms of ischemic neuropathy. CTS is a common condition where regional compression at the wrist results in ischemic focal demyelination of the distal median nerve. This results in sensory dysfunction, pain, and eventually axon loss and weakness if the compression is sufficiently severe and prolonged. Standard therapy for CTS includes wrist splints, regional lidocaine injections, ergonomic adjustments, various forms of occupation therapy, and ultimately surgical release of the carpal tunnel ligament. However, all of these are either temporary in their effect or invasive. The diagnosis of CTS relies on clinical, electrodiagnostic or NCS, and ultrasound methods.

Study Design

Study Type:
Interventional
Actual Enrollment :
10 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Intraneural Facilitation as a Treatment for Carpal Tunnel Syndrome
Actual Study Start Date :
Jan 29, 2018
Actual Primary Completion Date :
Feb 22, 2019
Actual Study Completion Date :
Feb 22, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intraneural facilitation therapy

The intraneural facilitation intervention is a novel manual physical therapy approach with anecdotal evidence in neuropathic pain symptoms through biasing blood flow from an artery through the nutrient vessels into the epineurium of an accompanying nerve. The main concept of intraneural facilitation is the use of two manual holds. The first hold is called facilitation hold and includes putting the contralateral joint in a maximal loose-pack position that is comfortable to the patient. The hypothesis with this initial hold is the nerve will have greater excursion the accompanying artery and the nutrient vessels that are clustered at the joint will be stretched. This stretch may enlarge the opening at the junction of the artery and bridging nutrient vessel, therefore consistently creating a vascular bias into the neural epineurial capillaries. Theoretically, this creates increased epifascicular vascular pressure which may be absent due to epineurial ischemia.

Other: Intraneural facilitation (INF)
INF is a novel non-invasive therapy based on the principle of restoring vascular function at the capillary level in peripheral nerve.

Sham Comparator: Sham therapy

Will be performed by a different therapist than actual INF. The patient will be asked to do the following combination of passive range of motion (PROM) and active ROM activities to promote blood flow in the affected arm Each visit will last about 45 minutes, twice a week for 6 weeks (total 12 sessions). Missing > 4 sessions will invalidate subject outcomes.

Other: Sham INF
Will be performed by a different therapist than actual INF. The patient will be asked to do the following combination of passive range of motion (PROM) and active ROM activities to promote blood flow in the affected arm.

Outcome Measures

Primary Outcome Measures

  1. The Boston CTS Questionnaire symptom severity scale and functional assessment. [change between baseline and one week after completion of INF therapy]

    composite measurement of carpal tunnel symptomology (pain and numbness) and functional assessment

  2. The Boston CTS Questionnaire symptom severity scale and functional assessment. [change between week 1 and 3 months after completion of INF therapy]

    composite measurement of carpal tunnel symptomology (pain and numbness) and functional assessment

Secondary Outcome Measures

  1. Visual analog scale (VAS) [change between baseline and one week after completion of INF therapy]

    an ordinal standardized scale grading pain from 0 (absent) to 10 (greatest)

  2. Visual analog scale (VAS) [change between week 1 and 3 months after completion of INF therapy]

    an ordinal standardized scale grading pain from 0 (absent) to 10 (greatest)

  3. Ultrasound [change between baseline and one week after completion of INF therapy]

    Reduction in diameter of the median nerve at the wrist or in the distal forearm ratio

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years to 74 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Patients referred to the LLUH Neurology Electrodiagnostic Laboratory with electrodiagnostic and clinical evidence of CTS (uni- or bilateral)

  2. Ages >18 and < 75 (irrespective of gender)

  3. Current use of splints as long as the frequency of treatment is unaltered and onset of use is > 1 week in duration

Exclusion Criteria:
  1. Prior carpal tunnel release > 2 years ago

  2. The presence of any condition that would prevent NCS from accurately diagnosing CTS (e.g., hereditary polyneuropathy or acquired demyelinating polyneuropathy)

  3. Workman's Compensation cases

  4. Pregnancy

  5. Undergoing conservative or surgical/injection therapy (physical or occupational therapy, injections)

  6. Clinically silent CTS in face of positive electrodiagnostic results

  7. Sufficiently severe clinical symptoms that warrant more aggressive therapy i.e., carpal injections or release

  8. Any confounding medical condition that the investigator deems may adversely affect subject participation or outcomes

Contacts and Locations

Locations

Site City State Country Postal Code
1 Loma Linda University Health Loma Linda California United States 92354

Sponsors and Collaborators

  • Loma Linda University

Investigators

  • Principal Investigator: Bryan Tsao, MD, Loma Linda University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Bryan Tsao, Neurology Chairman, Loma Linda University
ClinicalTrials.gov Identifier:
NCT03205683
Other Study ID Numbers:
  • 5170247
First Posted:
Jul 2, 2017
Last Update Posted:
Sep 10, 2019
Last Verified:
Sep 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 10, 2019